文献速递免疫规划卫生政策与健康促进

疫苗佐剂系统:13年上市后经验推动佐剂疫苗安全性研究

Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood.
PubMed 文献 · Vaccine · 2019-08-13

综述总结含佐剂系统(AS04、AS03、AS01)疫苗自2005年上市以来在不同人群中的安全性经验,涉及乙肝、HPV、疟疾、带状疱疹和流感疫苗。13年应用表明其安全性可接受,安全性评估方法随新技术进步而发展,为新佐剂疫苗研发提供标准。

要点

  • 含AS04、AS03或AS01的疫苗已在多国获批并纳入免疫规划,覆盖多种疾病和不同目标人群。
  • 同一佐剂在不同疫苗或人群中的安全性不可外推,佐剂安全性评估面临特殊挑战。
  • 13年上市后经验支持含AS疫苗的安全性可接受,安全性评估方法不断进步。

核心结论

  • 13年含佐剂系统疫苗的使用经验表明其安全性可接受。
  • 佐剂安全性评估方法的发展推动了疫苗安全性研究和调查方式的进步。

研究设计与样本

  • 综述,回顾佐剂系统(AS)从临床开发到上市后安全性评估的挑战与应对。
  • 涵盖2005年首款含AS04疫苗上市至2018年间获批的含AS04、AS03或AS01的疫苗。

主要发现

  • 含AS04、AS03或AS01的疫苗已针对乙肝、人乳头瘤病毒、疟疾、带状疱疹和(大流行前)流感等疾病获批。
  • 这些疫苗的目标人群包括肾损伤个体、女孩和年轻女性、非洲婴幼儿和儿童、50岁及以上成人及一般人群。
  • 自2005年以来,含AS疫苗在国家免疫规划和大流行场景中积累了安全性经验。

临床怎么用

  • 同一佐剂在不同疫苗或人群中的安全性不可直接外推,需针对具体疫苗和人群评估。
  • 新佐剂疫苗开发可参考已建立的佐剂安全性评估标准和方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adjuvant Systems (AS) are combinations of immune stimulants that enhance the immune response to vaccine antigens. The first vaccine containing an AS (AS04) was licensed in 2005. As of 2018, several vaccines containing AS04, AS03 or AS01 have been licensed or approved by regulatory authorities in some countries, and included in vaccination programs. These vaccines target diverse viral and parasitic diseases (hepatitis B, human papillomavirus, malaria, herpes zoster, and (pre)pandemic influenza), and were developed for widely different target populations (e.g. individuals with renal impairment, girls and young women, infants and children living in Africa, adults 50 years of age and older, and the general population). Clearly, the safety profile of one vaccine in one target population cannot be extrapolated to another vaccine or to another target population, even for vaccines containing the same adjuvant. Therefore, the assessment of adjuvant safety poses specific challenges. In this review we provide a historical perspective on how AS were developed from the angle of the challenges encountered on safety evaluation during clinical development and after licensure, and illustrate how these challenges have been met to date. Methods to evaluate safety of adjuvants have evolved based on the availability of new technologies allowing a better understanding of their mode of action, and new ways of collecting and assessing safety information. Since 2005, safety experience with AS has accumulated with their use in diverse vaccines and in markedly different populations, in national immunization programs, and in a pandemic setting. Thirteen years of experience using antigens combined with AS attest to their acceptable safety profile. Methods developed to assess the safety of vaccines containing AS have progressed the way we understand and investigate vaccine safety, and have helped set new standards that will guide and support new candidate vaccine development, particularly those using new adjuvants. FOCUS ON THE PATIENT: What is the context? Adjuvants are immunostimulants used to modulate and enhance the immune response induced by vaccination. Since the 1990s, adjuvantation has moved toward combining several immunostimulants in the form of Adjuvant System(s) (AS), rather than relying on a single immunostimulant. AS have enabled the development of new vaccines targeting diseases and/or populations with special challenges that were previously not feasible using classical vaccine technology. What is new? In the last 13 years, several AS-containing vaccines have been studied targeting different diseases and populations. Over this period, overall vaccine safety has been monitored and real-life safety profiles have been assessed following routine use in the general population in many countries. Moreover, new methods for safety assessment, such as a better determination of the mode of action, have been implemented in order to help understand the safety characteristics of AS-containing vaccines. What is the impact? New standards and safety experience accumulated over the last decade can guide and help support the safety assessment of new candidate vaccines during development.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Laupèze B, Hervé C, Di Pasquale A, et al. Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood. Vaccine. 2019. PMID: 31420171. doi:10.1016/j.vaccine.2019.07.098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。